Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Elite Pharmaceuticals Inc. (ELTP) had Revenue of $56.63M for the most recently reported fiscal year, ending 2024-03-31.

Quarterly Annual

Figures for fiscal year ending 2024-03-31

Income Statement Financials
Revenue	$56.63M
Net Income	$20.11M
Cost of Goods Sold	$30.27M
Gross Profit	$26.36M
Operating Expenses	$45.84M
Operating Income	$10.79M
Non-Operating Income/Expense	$-10.33M
Pre-Tax Income	$0.46M
Normalized Pre-Tax Income	$0.46M
Income after Taxes	$20.11M
Income from Continuous Operations	$20.11M
Consolidated Net Income/Loss	$20.11M
Normalized Income after Taxes	$20.11M
EBIT	$10.79M
EBITDA	$12.26M
Weighted-Average Shares Outstanding (Basic)	1.02B
Weighted-Average Shares Outstanding (Diluted)	1.02B
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.02
Balance Sheet Financials
Current Assets	$40.01M
Property, Plant, and Equipment	$10.18M
Long-Term Assets	$43.64M
Total Assets	$83.65M
Current Liabilities	$13.05M
Long-Term Debt	$4.76M
Long-Term Liabilities	$13.02M
Total Liabilities	$26.07M
Common Equity	$57.58M
Tangible Shareholders Equity	$51.24M
Shareholders Equity	$57.58M
Common Shares Outstanding	1.07B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-3.28M
Cash Flow from Investing Activities	$-0.81M
Cash Flow from Financial Activities	$3.39M
Beginning Cash	$8.24M
End Cash	$7.54M
Increase/Decrease in Cash	$-0.71M
Stock-Based Compensation	$8.51M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.07
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.08
Debt to Equity Ratio	0.16
Gross Margin	46.55%
Operating Margin	19.05%
EBIT Margin	19.05%
EBITDA Margin	21.65%
Pre-Tax Profit Margin	0.82%
Profit Margin	35.51%
Free Cash Flow	$-4.09M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.68
Inventory Turnover	2.34
Receiveable Turnover	2.91
Days Sales in Receivables	125.39
Return on Equity	34.92%
Return on Tangible Equity	39.24%
Return on Assets	24.04%
Return on Investments	32.25%
Book Value Per Share	$0.05
Free Cash Flow per Share	$-0.00
Operating Cash Flow per Share	$-0.00

Data from Zacks Investment Research, Inc.